New Study Links Intestinal Cannabinoid Receptors to Alcohol-Induced Leaky Gut
BETHESDA, MD, UNITED STATES, May 7, 2025 / EINPresswire.com / -- Heavy alcohol consumption is a leading cause of gastrointestinal diseases, with binge drinking linked to increased intestinal permeability—a condition commonly known as 'leaky gut.' Despite the significant health impact of alcohol-associated gastrointestinal disorders, effective pharmacological treatments remain limited. A new study published in eGastroenterology explores the role of gut cannabinoid receptor 1 (CB1R) in alcohol binge-induced intestinal permeability and reveals how its inhibition can help protect the gut barrier.
The research, conducted by scientists from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) at the National Institutes of Health (NIH), demonstrates that alcohol bingeing increases endocannabinoid levels in the proximal small intestine, triggering CB1R activation in intestinal epithelial cells. This activation disrupts tight junction proteins, which generally maintain the integrity of the gut lining, leading to increased intestinal permeability. This process can allow harmful substances, such as bacteria and toxins, to enter the bloodstream, contributing to inflammation and other health complications.
To investigate the role of CB1R, the researchers developed genetically modified mice with intestinal epithelial-specific CB1R deletion (CB1IEC−/− mice). They found that alcohol bingeing significantly increased gut permeability in normal mice, but this effect was absent in CB1IEC−/− mice, indicating that CB1R is a key mediator of alcohol-induced leaky gut.
Additionally, the study examined the effects of pharmacological CB1R inhibition using a peripherally restricted CB1R antagonist (S)-MRI-1891. When administered to normal mice before alcohol bingeing, this compound successfully prevented the increase in intestinal permeability. However, the drug had no effect in CB1IEC−/− mice, further confirming that CB1R in the intestinal epithelium is responsible for alcohol-induced gut barrier disruption.
Mechanistic studies revealed that CB1R activation in the gut epithelium triggers the ERK1/2 signalling pathway, which leads to the downregulation of tight junction proteins and a reduction in villus length—key factors contributing to a leaky gut. By inhibiting CB1R, researchers could reverse these changes, restoring gut barrier function and improving overall gut health.
These findings hold significant implications for the treatment of alcohol-related digestive disorders. Currently, there are no FDA-approved drugs specifically designed to treat alcohol-induced intestinal permeability. The study suggests that targeting CB1R with peripherally restricted antagonists could provide a novel therapeutic approach, potentially preventing systemic inflammation and other complications associated with alcohol-induced gut barrier dysfunction.
These insights could have broader applications in gastrointestinal health beyond alcohol-related gut disorders. The endocannabinoid system is known to influence gut motility, immune function, and microbiota composition, and its role in intestinal permeability suggests that CB1R inhibition may be beneficial in other conditions characterized by increased gut permeability, such as inflammatory bowel disease and metabolic disorders.
However, the study also highlights some limitations. While CB1R inhibition effectively prevented alcohol-induced leaky gut, it did not significantly impact metabolic parameters or liver disease progression. This suggests that although a leaky gut contributes to alcohol-related health issues, other mechanisms are also at play in the development of liver disease and metabolic dysfunction.
Future research will explore whether combining CB1R inhibitors with other therapeutic strategies could offer more comprehensive protection against alcohol-induced organ damage. Additionally, further studies are needed to assess the long-term safety and efficacy of CB1R antagonists in clinical settings.
This groundbreaking study advances our understanding of the gut's response to alcohol and opens new avenues for targeted therapies. By identifying CB1R as a crucial mediator of alcohol-induced intestinal permeability, researchers have paved the way for potential pharmacological interventions that could help mitigate the harmful effects of binge drinking on gut health.
Funder
The authors received financial support from the Intramural Program of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), NIH (Grant Nos. AA00350, AA000369, AA000368), the National Research, Development and Innovation Office (Grant No. PD-139012) and the János Bolyai Research Scholarship of the Hungarian Academy of Sciences.
See the article:
Maccioni L, Dvorácskó S, Godlewski G, et al. Gut cannabinoid receptor 1 regulates alcohol binge-induced intestinal permeability. eGastroenterology 2025;3:e100173. doi:10.1136/egastro-2024-100173
eGastroenterology is a new, open-access, and open peer-reviewed BMJ Journal, which focuses on basic, clinical, translational, and evidence-based medicine research in all areas of gastroenterology (including hepatology, pancreatology, esophagology, and gastrointestinal surgery).
For more information, please visit: egastroenterology.bmj.com and follow us on Twitter (@eGastro_BMJ).
Contact:
Dr. Bin Gao
National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health
Bethesda, Maryland, USA
Email: [email protected]
Dr. George Kunos
National Institute on Alcohol Abuse and Alcoholism
[email protected]
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
3 hours ago
- Business Insider
Sarepta says eight-year-old death deemed unrelated to Elevidys
Sarepta (SRPT) said in a statement Friday night: 'Just before 6:00 p.m. ET today, the U.S. Food and Drug Administration issued a press release announcing an investigation into the death of an eight-year-old Duchenne muscular dystrophy patient who had received Elevidys gene therapy. The death of this patient was deemed unrelated to treatment with Elevidys…Sarepta reported this event to FDA on June 18, 2025, via the FDA's postmarketing electronic database, FAERS. At Sarepta, patient safety and well-being are always our top priority. We are committed to upholding the highest safety standards for all of our therapies, and do so in accordance with applicable law and commitment to full regulatory transparency. Elevidys is the only approved gene therapy for families and children devastated by Duchenne, a rare, progressive and ultimately fatal disease. We remain committed to working closely with the FDA to ensure that all decisions are grounded in science and the best interests of patients, considering the compelling need of these families to access disease-modifying therapy.' Elevate Your Investing Strategy:
New York Post
3 hours ago
- New York Post
Breakthrough as two FDA-approved drugs are found to reverse Alzheimer's — including restoring memory
In a stunning scientific discovery, researchers have found that a pair of drugs can not only slow down Alzheimer's disease but actually reverse it and restore memory in mice. And the best part of all? Both are already FDA-approved — albeit for cancer. Researchers first pinpointed how Alzheimer's disease scrambles gene activity in individual brain cells. 3 Researchers have found that a pair of drugs can not only slow down Alzheimer's disease but actually reverse it and restore memory in mice. Pixel-Shot – Using the Connectivity Map database of 1,300 FDA‑approved drugs, the researchers looked for medications that reverse Alzheimer's‑associated gene expression — landing on a shortlist of five, and zeroing in on two cancer drugs. In what one researcher called a 'mock clinical trial,' they then mined 1.4 million patients' medical records, finding that those who had taken letrozole or irinotecan for cancer were significantly less likely to develop Alzheimer's. When given together in an aggressive Alzheimer's mouse model, letrozole — used to treat certain types of breast cancer in postmenopausal women — and irinotecan — an anti-cancer medication used to treat colon cancer and small cell lung cancer — reversed disease‑related gene expression signatures, dissolved toxic tau protein clumps and prevented brain degeneration. Most importantly, they restored memory and learning in mice that had already developed severe symptoms. It's an exciting development for an illness that's notoriously tricky. 3 Letrozole — used to treat certain types of breast cancer in postmenopausal women — and irinotecan — an anti-cancer medication used to treat colon cancer and small cell lung cancer — reversed disease‑related gene expression signatures, dissolved toxic tau protein clumps and prevented brain degeneration. Eric Hood – 'Alzheimer's disease comes with complex changes to the brain, which has made it tough to study and treat, but our computational tools opened up the possibility of tackling the complexity directly,' Marina Sirota, the interim director of the UCSF Bakar Computational Health Sciences Institute, said in a statement. 'We're excited that our computational approach led us to a potential combination therapy for Alzheimer's based on existing FDA-approved medications.' 'Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health,' said Yadong Huang, a professor of neurology and pathology at UCSF. 'This makes it very challenging for drug development — which traditionally produces one drug for a single gene or protein that drives disease.' 3 'Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health,' said Yadong Huang, a professor of neurology and pathology at UCSF. yurakrasil – The findings were published in the journal Cell. Both drugs are already FDA‑approved for other uses, which could dramatically speed up the path to human trials. However, because they are cancer drugs, repurposing them may be complex and risky. This finding adds to a growing number of potential Alzheimer's treatments. A compound found in rosemary and sage — carnosic acid — has been shown to reverse memory loss and reduce brain inflammation in mice with Alzheimer's, bringing their cognitive function back to near-normal levels. A study from Stanford Medicine found that seniors who received the shingles vaccine were 20% less likely to develop dementia over seven years. And researchers at Penn State and Stanford University discovered that a certain cancer drug could restore memory and brain function in early stage Alzheimer's models.
Wall Street Journal
5 hours ago
- Wall Street Journal
Vinay Prasad Is a Bernie Sanders Acolyte in MAHA Drag
Meet Vinay Prasad, a young disciple of Bernie Sanders who ranks as one of the most powerful officials in the federal government. He determines whether patients get access to many life-saving medicines. Or not. Think of him as a one-man death panel. Dr. Prasad was named by Marty Makary, the Food and Drug Administration commissioner, as head of the agency's biologics division in May, and last month as its chief medical and scientific officer. More on why he was tapped to these posts later. But it isn't an exaggeration to say that Dr. Prasad wields more power than Anthony Fauci ever did at the National Institutes of Health.
